Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel with low-dose S-1 versus docetaxel alone in previously treated advanced non-small cell lung cancer
ChiCTR1900020759Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jan 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel and tegafur in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Progression-free survival. Started Jan 2019; status: recruiting.
02
Drugs
docetaxeltegafur
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900020759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020759.